Automated Point-of-Care CAR T-Cell Fabrication & Democratization

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Rich Fabian, president and CEO of FUJIFILM Sonosite, will serve as the chair of the Medical Imaging division’s board of directors. He will succeed David Pacitti, CEO of Avanos Medical and former president and head of the Americas at Siemens Healthineers, the inaugural division board chair.  

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Robert Cohen, vice president, innovation and technology, orthopaedic group at Stryker, will be the next chair of the AdvaMed Digital Health Tech Board of Directors. He succeeds Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare, who served as the inaugural chair of the board overseeing the then-newly created division.  

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.

Join EPAM as they explore how robust Human Factor practices can help teams navigate usability and compliance of products in an increasingly digital landscape.

NAPLES, Fla., Dec. 4, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that its Catalyst Fracture Shoulder System has received FDA 510(k) clearance for additional indications that now include anatomic (total or hemi) shoulder procedures, giving surgeons flexibility to treat complex proximal humeral fractures (PHFs) with a single, streamlined platform for both anatomic and reverse replacements. In anatomic indications, the Catalyst Fracture System utilizes Catalyst’s ellipsoid head design, shown to better restore natural anatomy compared to traditional spherical head designs on the market today.

AdvaMed’s 2025 Cybersecurity Summit gathered industry and regulatory leaders to explore today’s cyber threats and align on solutions. Key themes included FDA expectations, hospital security realities, and the cultural shifts needed to build a more resilient medtech ecosystem.

MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of prostate cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the Vanquish System for prostate tissue ablation. FDA clearance was supported by positive 12-month follow-up data on the first 110 patients enrolled in the company’s ongoing VAPOR 2 clinical study. The clearance marks a critical milestone for the company and enables a commercial launch of the Vanquish System.

WASHINGTON — AdvaMed, the medtech association, the world’s largest trade association representing medtech innovators, today released the following statement on the U.S. Centers for Medicare & Medicaid Services’ (CMS) release of its 2026 Home Health Prospective Payment System final rule: